3rd US-Japan Cooperative Cancer Research Symposium

Tobacco-Related Cancers
Sponsored by the Japan Society for the Promotion of Science (JSPS) and the National Cancer Institute (NCI)

Agenda
February 25-26, 2002
Natcher Auditorium on the NIH Campus

Monday, February 25
8:30 AM Welcome and Introductory Remarks Dr. Joe Harford, NCI
Dr. Andrew C. von Eschenbach, Director, NCI
Mr. Koji Nakanishi, JSPS
Special Lecture
Molecular Pathogenesis of Lung Cancer with Potential Translational Applications		 Dr. John Minna (Univ. of Texas Southwestern Medical Center, Dallas, TX)
9:45 AM Coffee Break
10:00 AM Session #1 : Molecular Biology of Tobacco-Related Cancers (30 min talks including questions)
Smoking Behavior and Its Molecular Consequences in the Pathogenesis of Lung Cancer Dr. Takashi Takahashi (Aichi Cancer Center Research Inst., Aichi, Japan)
Genetic Factors Involved in Lung Adenocarcinoma Susceptibility Dr. Takashi Kohno (National Cancer Center Research Inst., Tokyo, Japan)
Targeting the PI3K/Akt Pathway for Lung Cancer Prevention and Treatment Dr. Phillip Dennis - (NCI, Bethesda, MD)
Genetic Polymorphisms of Genes Involved in Repair of 8-Hydroxyquanine and Lung Cancer Susceptibility Dr. Kazuya Shinmura (National Cancer Center Research Inst., Tokyo, Japan)
Bypass synthesis of Benzo[a]pyrene Adducts by Human DNA Polymerase !!! Dr. Haruo Ohmori (Kyoto, Univ., Kyoto, Japan)
12 Noon Lunch Break
1 :30 PM Session #2: Treatment and Treatment Prospects for Tobacco-Related Cancers (30 min talks including questions)
Video-Assisted Thorascopy for Diagnosis and Treatment of Early Lung Cancer Dr. Jun Nakajima (Univ. Tokyo, Tokyo, Japan)
Molecular Epidemiology and Molecular Pathogenesis of Lung Cancer Dr. Curt Harris (NCI, Bethesda, MD)
Molecular Targeted Therapy for Control of Lung Cancer Metastasis in Different Organ Microenvironments Dr. Saburo Sone - (Univ. Tokushima Sch. Med, Tokushima, Japan)
Molecular Targeted Approaches to the Chemoprevention of Aerodigestive Tract Cancers. Dr. Fadlo Khuri (MD Anderson Cancer Ctr., Houston, TX)
3:30 PM-5:00 PM Posters and Reception with Refreshments

Tuesday, February 26
8:30 AM Special Lecture
Genetic Susceptibility to Tobacco Carcinogenesis		 Dr. Margaret Spitz (MD Anderson Cancer Ctr, Houston, TX)
9:30 AM Coffee Break
10:00 AM Session #3 - Epidemiology and Prevention I (30 min talks including questions)
Epidemiological Studies on Genetic Changes in Lung Cancer Patients Exposed to Cigarette Smoke and Asbestos Dr. Yuichi Ishikawa, Japanese Foundation for Cancer Research, Tokyo, Japan)
Lung Cancer Chemoprevention with Green Tea and Monitoring by a New Biomarker, hnRNP B1 Dr. Masami Suganuma (Saitama Cancer Center, Saitama, Japan)
Inducement to Quit Smoking by a Genetic Polymorphism Test on Susceptibility to Tobacco-Related Cancers Dr. Nobuyuki Hamajima (Aichi Cancer Center Research Institute, Aichi, Japan)
Genetics of Lung Cancer and Nicotine Addiction Dr. Neil Caporaso (NCI, Bethesda, MD)
12 Noon Lunch Break
1 :30 PM Session #4 - Epidemiology and Prevention II (30 min talks including questions)
Cigarette Smokers: Characteristics and Cancer Prevention Dr. Kazue Imai (Radiation Effects Research Foundation, Hiroshima Japan)
Comparative smoking-related lung cancer risks in the US and Japan Dr. Steven Stellman (American Health Foundation, Valhalla, NY, and Columbia University, New York, NY)
Risk Reduction in Lung Cancer by Age at Smoking Cessation: Findings from a Large Cohort Study in Japan (the JACC study) Dr. Kenji Wakai (Nagoya Univ. Sch. Med., Aichi, Japan)
3:00 PM Coffee Break
Reducing Tobacco Toxin Exposure: Strategies and Methods Dr. Dorothy Hatsukami (Univ. Minnesota, Minneapolis, MN)
Interventions Aimed at Tobacco Dependence Dr. David Abrams (Brown University, Providence, RI)
Overview of NCI's Tobacco-Control Efforts Dr. Scott Leischow (NCI, Bethesda, MD)
5:00 PM Adjourn


POSTER ABSTRACTS
February 25 3:30 - 5:00 p.m.

#1 Interventions Aimed at Tobacco Dependence
David Abrams
#2 Cigarette Smoking and Cervical Cancer: Geographic Variability Study and Meta-Analysis
Harry Haverkos
#3 Differentially Expressed Genes Associated with Carcinogen Induced Mouse Lung Tumors
Ronald Lubet
#4 Molecular Biomarkers for the Prevention of Mouse Lung Tumors by Budesonide
Ronald Lubet
#5 Cell Cycle Activation in Lung Carcinoma Cells by a Transforming Growth Factor
Gunamani Sithanandam

#1 "Interventions Aimed at Tobacco Dependence"
David B. Abrams, Ph.D.
Centers for Behavioral & Preventive Medicine Brown Medical School & The Miriam Hospital
ABSTRACT
Evidence-based smoking cessation interventions have the potential to significantly accelerate reductions in population prevalence of tobacco use and associated disease burden. Clinical practice guidelines have been developed in both Britain and the U.S. based on expert panel review and meta-analyses of over 6,000 cessation intervention trials. Results of the clinical practice guide, developed in the U.S. by the Agency for Health Research and Quality, reveal a number of effective and efficient pharmacological and behavioral interventions. These interventions and their efficacy will be presented. They range from minimal and inexpensive components, such as screening all smokers, to brief behavioral and pharmacological approaches to more intensive clinical treatments. However, as interventions vary from least to most intensive, the cost increases, as does the infrastructure required to implement these programs. The most intensive, effective and costly programs reach only a very small proportion of the smokers in a given population. Reducing overall population prevalence of tobacco use requires the appropriate allocation of fixed resources to reach the largest number of smokers with the appropriate level of treatment. The role of a stepped-care model for cessation interventions within a comprehensive tobacco control strategy will be discussed.


#2 Cigarette Smoking and Cervical Cancer: Geographic variability study and meta-analysis
Harry W. Haverkos (presenter), Pickworth W, Steckley S, Soon G Walter Reed Army Medical Center, Washington DC; National Institute on Drug Abuse, Baltimore, MD and FDA, Rockville, MD
In 1977, Winkelstein hypothesized that cigarette smoking was a causative factor for cervical cancer after noting a correlation between the age-adjusted incidence rates for cervical cancer and cancer of the lung in men and an association between female smoking and cervical cancer in four case-control studies.
PURPOSE: To investigate the relationships between smoking and cervical cancer through the review of ecological and epidemiologic data.
METHODS: Published rates of female smoking, cervical cancer and female lung cancer were correlated for the USA, Europe, and countries of the world. Data from 72 case-control studies of cervical disease were reviewed and odds ratios for cigarette smoking were calculated.
RESULTS: For ecological data, female smoking was positively correlated with cervical cancer in the USA, but not for Europe; female smoking was negatively correlated for 74 countries of the world.
World lung cancer
(n=74)		 World cervical Cancer
(n=74)		 US Lung cancer
(n=44)		 US cervical cancer
(n=44)		 Europe lung cancer
(n=30) 		Europe cervical cancer
(n=30)
female male female male female male
Cervical Cancer -.430* -.550* XXXX .470* .636* XXXX .079 .303 XXXX
% female smokers .399* .329* -.250* .523 * .561 * .203 .503* -.171 -.305
*=P < .05 Pearson's correlation table
For epidemiologic data, cigarette smoking was reported more often by cases than controls in studies from North America, Europe, and Asia. CONCLUSION: In summary, a role for cigarette smoking in the etiology of cervical cancer remains under study. The results of the ecological and epidemiologic studies of smoking and cervical cancer are compatible in the USA, but not elsewhere. (The opinion or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of Defense, or the Food and Drug Administration.)


#3 Differentially Expressed Genes Associated with Carcinogen Induced Mouse Lung Tumors: Results Obtained By Use Of CCLS (Comparative cDNA Library Screen) And Or Use Of A Small Microarray
Ruisheng Yao1, Yian Wang2, Ronald A. Lubet3, and Ming You1*
1Division of Human Cancer Genetics and 2School of public Health, The Ohio State University Comprehensive Cancer Center, 420 West 12th Avenue, Columbus, Ohio 43210. 3Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland 20892.
ABSTRACT
STUDY 1: DIFFERENTIALLY EXPRESSED GENES IN LUNG ADENOMAS EMPLOYING CCLS
A competitive cDNA library screening (CCLS) of normal mouse lung was employed to determine changes in the expression of mRNA in MNU-induced lung adenomas as compared with paired normal lung tissues. A total of 2,555 clones of over 160,000 examined showed altered expression in tumors. Among the 755 clones confirmed by dot blot hybridization, 240 clones were underexpressed, while 515 clones were overexpressed in tumors. Eighty-three clones with the most frequently altered expression in 10 individual tumors were selected for confirmation by semiquantitative RT-PCR. When examining "known" genes, 28 clones had increased expression and 13 had decreased expression, while for novel clones, 23 showed overexpression and 2 had decreased expression. A gene was considered to show reproducibly altered expression if > 70% of tumors displayed increased or decreased expression relative to normal lung tissue. Reproducibly over expressed genes included erk- 1 , JAK1, surfactant protein A, B and C, NFAT 1 , alpha- 1 protease inhibitor , helix-loop-helix ubiquitous kinase (CHUK),!!!-adaptin,!!!-1 PI2, thioether S-methyltransferase, and CYP2C40. Reproducibly underexpressed genes included paroxanase. Aldehyde dehydrogenase II, CC10, VonEbner salivary gland prtein and alpha and beta globin. This study shows the efficacy of this methodology for identifying genes with altered expression.


#4 Molecular Biomarkers for the Prevention of Mouse Lung Tumors by Budesonide.
M. A. Pereira1,Y. Li1, F. S. Al-Yaqoub1, W. T. Gunning1, P. M. Kramer1, W. Wang1, R. A. Lubet2, V. E. Steele2, E. Szabo2 and L. Tao1.
1Department of Pathology, Medical College of Ohio and 2Division of Cancer Prevention, NCI

The discovery of chemopreventive drugs could be expedited by the use of biomarkers that demonstrate chemopreventive efficacy. The modulation of biomarkers by budesonide in mouse lung tumors was determined. Female strain A mice were administered 16 mg/kg vinyl carbamate for two consecutive weeks. Budesonide (2.4 mg/kg diet, a dose that prevented lung tumors in mice) was administered for only the last seven days prior to sacrifice at Week 35. The Proliferating Cell Nuclear Antigen (PCNA)-labeling Index was decreased by budesonide in carcinomas (59.0%) , adenomas (77.6%), airways (25.4%), and parenchyma (41.1%). In lung tumors, budesonide increased the protein level of p21Cip/Waf1/sdi1 and p27Kip1 and the mRNA level of p21. Using the bisulfite-treated DNA sequencing procedure, normal lung tissue had Å`20 of 24 CpG sites methylated in the differentially methylated region 2 of the insulin-like growth factor-2 (IGF-II) gene. Lung tumors had only 0-2 of the CpG sites methylated, while budesonide increased the number of methylated sites to 13-16. Hpa áTáT digestion of DNA from normal lung tissue did not result in any bands on Southern blot analysis when probed for c-myc, while three bands were present in digested DNA from lung tumors. Budesonide decreased the intensity of the three bands from DNA. Thus, potential biomarkers for chemoprevention of lung cancer include the ability to increase the protein levels of p21 and p27, the mRNA level of p21 and the methylation of the IGF-II and c-myc genes in tumors, and to decrease the PCNA-labeling in tumors and normal appearing airways and parenchyma.

#5 Cell Cycle Activation in Lung Carcinoma Cells by a Transforming Growth Factor!!/ErbB3/Phosphatidylinositol 3 kinase/Akt Pathway
Gunamani Sithanandam1*, George T. Smith2, Laura W. Fornwald1 and Lucy M. Anderson2
1Intramural Research Support Program, SAIC Frederick and 2Laboratory of Comparative Carcinogenesis, National Cancer Institute, Frederick MD 21702-1201, USA

An autocrine loop involving epidermal growth factor receptor and transforming growth factor is implicated in the pathogenesis of human lung adenocarcinoma, and overexpression of transforming growth factor!!together with ErbB2 or ErbB3 may be associated with poor prognosis. In mouse lung adenocarcinoma cell line E9 we found high expression of both transforming growth factor!!and ErbB3, whereas both were absent from the non-transformed sister line E10. Both lines expressed epidermal growth factor receptor, ErbB2 and ErbB4. Exogenous transforming growth factor!!treatment of E9 cells stimulated epidermal growth factor receptor phosphorylation, and formation of complexes containing phosphorylated ErbB2, phosphorylated ErbB3, and the p85 regulatory subunit of phosphoinositidyl 3 kinase, as indicated by co-immunoprecipitation experiments. Transforming growth factor!!also stimulated phosphorylation of Akt and GSK3!!, increase in cyclin D1 , and cell cycle progression, and these events were blocked by the ErbB receptor inhibitor PD 153035 and the Akt activation inhibitor LY294002. In human NSCLC cell lines H441 and H1373, pErbB3/p85 complexes were detected, and treatment with LY294002 blocked cell cycle progression. These results suggest involvement of ErbB3 in growth of lung adenocarcinomas, through activation of phosphoinositidyl 3 kinase and Akt, inactivation of GSK3!!, and stabilization of cyclin D1 for cell cycle maintenance.


PARTICIPANTS LIST

DAVID ABRAMS. PH.D.
Director, Centers for Behavioral and Preventive Medicine Brown Medical School & The Miriam Hospital Lifespan Academic Medical Center One Hoppin Street The Coro Building, Suite 500 Providence, RI 02903 Phone: 401-793-8005 Fax: 40 1 -793-8056 Email: David_Abrams@brown.edu

LUCY ANDERSON
National Cancer Institute Fort Detrich, Building 538 Frederick, MD 20702 Phone: 301-846-5600 Fax: 301-846-5946 Email: Andersol@mail.ncifcrf.gov

YUICHI ANDO
National Cancer Institute 9000 Rockville Pike Room 10-5AOI Bethesda, MD 20892 Phone: 301-402-3622 Fax: 301-402-8606 Email: yando@mail.nih.gov

CATHY BACKINGER
National Cancer Institute 6130 Executive Blvd. Room 4036 MSC 7337 Bethesda, MD 20892 Phone: 301-496-8584 Fax: 301-496-8675 Email: backingc@mail.nih.gov

NIKHIL BASU
National Institute of Child Health and Human Development 9000 Rockville Pike Building 10, Room 9S-241-8D-57 Bethesda, MD 20892 Phone: 301-496-6091 Fax: 301-480-8092 Email: basun@mail.nih.gov

SHARMILA BASU
National Human Genome Research Institute 9000 Rockville Pike Building 50, Room 5222B Bethesda, MD 20892 Phone: 301-496-8837 Fax: 301-480-1109 Email: sharmib@nhgri.nih.gov

DAVID BERMAN
National Cancer Institute 10 Center Drive Building 10, Room 2N212 Bethesda, MD 20892 Phone: 301-496-0999 Fax: 301-480-9488 Email: bermand@mail.nih.gov

MARIA CANTO
National Institute on Dental and Craniofacial Research 45 Center Drive Building 45, Room 4AN24K Bethesda, MD 20892 Phone: 301-594-5497 Fax: 301-480-8318 Email: maria.canto@nih.gov

NEIL CAPORASO
Chief of Parmacogentics Section & Sr. Investigator National Cancer Institute 6130 Executive Blvd., EPS, Room 7116 Bethesda, MD 20892 Phone: 301-496-4377 Fax: 301-402-4489 Email: caporasn@epndce.nci.nih.gov

NADIA CHANDHRI
National Cancer Institute 505 Center Drive Building 50, Room 1306 Bethesda, MD 20892 Phone: 301-435-5835 Fax: 301-402-1204 Email: nadia@mail.nih.gov

KOICHI FUKUI
Japan Society for the Promotion of Science Research Cooperation Division Japan 102-8471 Phone: 81-3-3263-1275 Fax: 81-3-3263-1673 Email: kenkyouka07@jsps.go.jp

VICTOR FUNG
Center for Scientific Review 6701 Rockledge Drive, Room 4120 Bethesda, MD 20814 Phone: 301-435-3504Å@Fax: 301-480-2564Å@Email: vf6n@nih.gov

YUKO FURUKAWA
Japan Society for the Promotion of Science International Programme Department Japan Phone: 81-3-3263- 1697Å@Fax: 81 -3-3263- 1673Å@Email: furukawa@jsps.go.jp

MARY GANT
National Institute of Environmental Health Sciences 31 Center Drive Building 31, Room B1C02 MSC 2256 Bethesda, MD 20892 Phone: 301 -496-2919Å@Email: gant@niehs.nih.gov

ABELARDO GARCIA
National Institute on Dental and Craniofacial Research 30 Convent Drive Bethesda, MD 20892 Email: sg39v@nih.gov

ROOP GILL
National Institute on Deafness and Other Communication Disorders 9000 Rockville Pike Building 10, Room 5D50 Bethesda, MD 20892 Phone: 301 435-2074 Fax: 301 402-1140Å@Email: gillr@nidcd.nih.gov

JOE GITCHELL
Pinney Associates, Inc. 4800 Montgomery Lane Suite 1000 Bethesda, MD 20814 Phone: 301-718-8440 Fax: 301-718-0034 Email: jgitchel@pinneyassociates.com

RADOSLAV GOLDMAN
Georgetown University Medical Center 3970 Reservoir Road, N.W. NRB, W309A Washington, DC 20007 Phone: 202-687-9868 Fax: 202-687-3669 Email: rg26@georgetown.edu

PETER GREENWALD
National Cancer Institute 6130 Executive Blvd. Executive Plaza North, Room 2040 Bethesda, MD 20892 Phone: 301-496-6616 Fax: 301-496-9931 Email: pg37@nih.gov

SIMONE GUERAMl
Clinical Center 9600 Rockville Pike Building 10, Room 2C525 Bethesda, MD 20892 Phone: 301-496-5646 Fax: 301-480-1699 Email: sguerami@nih.gov

SILVIO GUTKIND
National Institute on Dental and Craniofacial Research 30 Convent Drive Bethesda, MD 20892 Phone: 301-496-3695 Fax: 301-402-0823 Email: sg39V@nih.gov

BASSEM HADDAD
Georgetown University 3800 Reservoir Road, N.W. Main 4000 Washington, DC 20008 Phone: 202-784-1750 Fax: 202-784-1770 Email: haddadb1@georgetown.edu

CARRIE HUNTER
Georgetown University 3800 Reservoir Road, N.W. Room 8-148 Washington, DC 20007 Phone: 202-687-2283 Fax: Email: cph8@georgetown.edu

KAZUE IMAl
Scientific Researcher Radiation Effects Research Foundation 5-2 Hijiyamako, Inamachi, Kitaadachi-gun Saitar, Japan 732-0815 Phone: 81-82-261-1937 Fax: 81-82-262-9768 Email: kimai@rerf.or.jp

HIROSHI ISHIDA
Walter Reed Army Institute of Research 503 Robert Grant Avenue Silver Spring, MD 20910 Phone: 301-319-9621 Fax: 301-319-9449

HIROTSUGU ISHIDA
Ministry of Health, Labor and Welfare 1-2-2 Kasumigaseki Chiyoda-ku Tokyo, Japan 100-8916 Phone: 81-3-3595-2171 Fax: 81-3-3503-0183 Email: hirotsugu-ishida@mhlw.go.jp

YUICHI ISHIKAWA
Associate Member The Cancer Institute Japanese Foundation for Cancer Research 1-37-1 Kamiikebukuro, Toshima-ku Nagoya, Japan 170-8455 Phone: 81-3-3918-0111 (4324) Fax: 81 -3-5394-3923 Email: ishikawa@ifcr.or.jp

JEAN JENKINS
National Cancer Institute 8901 Wisconsin Avenue Building 8, Room 5101 NNMC Bethesda, MD 20889-5105 Phone: 301-496-0921 Fax: 301-496-0047 Email: jean.jenkins@nih,gov

JOSE JERONIMO
Environmental Epidemiology Branch 6120 Executive Blvd., Room 7088 Rockville, MD 20852 Phone: 301-402-7482 Fax: Email: guibovij@mail.nih.gov

BU-TIAN Ji
National Cancer Institute 6120 Executive Blvd. Executive Plaza South, Room 8120 Bethesda, MD 20892 Phone: 301-496-9093 Fax: 301-402-1819 Email: jib@exchange.nih.gov

TSUYOSHI KAKEFUDA
National Cancer Institute 14901 River Road Potomac, MD 20854 Phone: 301-926-0226 Fax: 301-926-0728 Email: kakefudt@msn.com

THEA KALEBIC
National Cancer Institute Bethesda, MD 20892 Phone: 301-496-0069 Fax: 301-480-3924 Email: kalebict@ctep.nci.nih.gov

KARTHIKEYAN KANDASAMY
University of Maryland 20 North Pine Street Baltimore, MD 21201 Phone: 410-706-8587 Fax: 410-706-0346 Email: kkandasa@rx.umaryland.edu

ERIK KASS
National Institute on Deafness and Other Communication Disorders 10 Center Drive Run 5C400, Building 10 Bethesda, MD 20892 Phone: 301-402-4317 Fax: 301-402-0409 Email: ek103b@nih.gov

SCOTT LEISCHOW, PH.D.
Chief, Tabacco Control Research Branch National Cancer Institute 6130 Executive Blvd. Executive Plaza North, Room 4038 Rockville, MD 20852 Phone: 301-496-8584 Fax: 301-496-8675 Email: SL83P@nih.gov

CONNIE LIANG
National Cancer Institute Building 567, Room 273 Frederick, MD 21702 Phone: 301 -846-1758 Email: liangc@ncinfr.gov

KATALIN LINDMAYER NABl
12276 Wilkins Avenue Rockville, MD 20852 Phone: 301-255-6916 Fax: 301 -770-0155 Email: klindmay@nabi.com

ILONA LINNOILA
National Cancer Institute 9610 Medical Center Drive, Suite 300 Rockville, MD 20850 Phone: 301-402-3128 X313 Fax: 301-402-4422 Email: il17honih.gov

ALEXIS LOCKSHIR
National Institute of Environmental Health Sciences 2000 Hungton Avenue Alexandria, VA 22305 Phone: 301-613-0876 Fax: Email: alockshir@indiana.edu

JAY LUBIN
National Cancer Institute 6120 Executive Blvd. Executive Plaza South, Room 8042 Rockville, MD 20892 Phone: 301-496-3357 Fax: 301-402-0081 Email: lubinJ@mail.nia.gov

ELISE LUONG
National Human Genome Research Institute 49 Convent Drive, Room 4A51 Bethesda, MD 20892 Phone: 301-402-2017 Fax: 301-402-2170 Email: eluong@nhgri.nih.gov

STEPHEN MARCUS
National Cancer Institute 6130 Executive Blvd., Rm 4046, MSC 7337 Bethesda, MD 20892 Phone: 301-496-8584 Fax: 301-496-8675 Email: marcusst@mail.nih.gov

AIZEN MARROGl
Food and Drug Administration 9600 Rockville Pike Building 29A, Room 2B-01 Bethesda, MD 20892 Phone: 301 -827-5194 Fax: 301-480-3256 Email: marrogi@cher.fda.gov

JAMES McKEARNEY
National Cancer Institute 6130 Executive Blvd. Suite 100 Bethesda, MD 20892 Phone: 301-496-6344 Fax: 301-496-3954 Email: jmck@helix.nih.gov

JOHN MINNA, M.D.
Director, Hamon Center for Therapeutic Oncology Research Univ. of Texas, Southwestern Medical Center 6000 Harry Hines Blvd. Dallas, TX 75390 Phone: 214-648-4900 Fax: 214-648-4940 Email: john.Minna@UTSouthwestern.edu

TERRY MOODY
National Cancer Institute 31 Center Drive Building 3, Room 3A34 Bethesda, MD 20892 Phone: 301-451-9451 Fax: 301-480-4323 Email: moodyt@mail.nih.gov

ANA RAIMONDI
University of Buenos Aires MI Alvear 2142 Buenos Aires, Argentina 01122 Phone: 54-11-4964-1273 Fax: 54-11-45-08-3958 Email: rosar71@yahoo.com

BRITT REID
National Institute on Dental and Craniofacial Research 10 Center Drive Building 45 Bethesda, MD 20892 Phone: 301-594-7705 Fax: 301-480-8322 Email: reidbritt@hotmail.com

JERRY RICE
International Agency for Research on Cancer 150 Cours Albert Thomas 69372 Lyon (Cedex 08), France Phone: 33 47273 8476 Fax: 33 47273 8319 Email: rice@iarc.fr

BARBARA RIMER
National Cancer Institute 6130 Executive Blvd., Room 6138 Rockville, MD 20852 Phone: 301-594-6776 Fax: 301-594-6787 Email: brimer@nih.gov

SUSAN RUDY
National Institute on Deafness and Other Communication Disorders 10 Center Drive Building 10, Room 5C402 Bethesda, MD 20892 Phone: 301-496-5368 Fax: 301-402-0409 Email: rudys@nidcd.nih.gov

ELIZABETH SALOOM
National Cancer Institute 31 Center Drive Building 31, Room 10A31 Bethesda, MD 20910 Phone: 301-496-2149 Fax: 301-402-4945 Email: saloome@mail.nih.gov

IHANANJAYA SARANATH
National Institute on Dental and Craniofacial Research 30 Convent Drive Bethesda, MD 20892 Phone: Fax: Email: sg39v@nih.gov

SAMIR SAUMA
National Cancer Institute 31 Center Drive Building 31 , Room 3A30 Bethesda, MD 20892 Phone: 301-402-7518 Fax: 301-435-3861 Email: saumas@nih.gov

SCOTT SAXMAN
National Cancer Institute 6130 Executive Blvd. Room 7025 Bethesda, MD 20892 Phone: 301-496-2522 Fax: 301-402-0557 Email: saxmans@ctep.nci.nih.gov

BEVERLY SCHAFF
National Cancer Institute 6130 Executive Blvd. Suite 100 Bethesda, MD 20892 Phone: 301-496-2128 Fax: 301-496-3954 Email: schaffb@exchange.nih.gov

MARGARET SPITZ, M.D.
Department of Epidemiology University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd., Box 189 Houston, TX 77030 Phone: 713-792-3020 Fax: 713-792-0807 Email: mspitz@mdanderson.org

EVA STABO
National Cancer Institute 6130 Executive Blvd., Room 2132 Bethesda, MD 20892 Phone: 301-435-2456 Fax: 301-480-3924 Email: staboe@mail.nih.gov

VAURICE STARKS
National Cancer Institute 6130 Executive Blvd., Room 5103 Bethesda, MD 20877 Phone: 301-496-9600 Fax: 301-402-4279 Email: vs38J@nih.gov

STEVEN STELLMAN, PH.D.,
MPH Professor of Epidemiology Columbia University Mailman School of Public Health 630 West 168th Street PH-18 New York, NY 10032 Phone: 212-305-4911 Fax: 212-305-9413 Email: sds91@columbia.edu

FRANCES STILLMAN
Johns Hopkins Bloomberg School of Public Health 615 North Wolfe Street Baltimore, MD 21205 Phone: 410-614-5378 Fax: 410-955-4662 Email: fstillma@jhsph.edu

KURT STROMBERG
Food and Drug Administration 5600 Fishers Lane Building 29A, Room 3B-201 Bethesda, MD 20892 Phone: 301 -827-1760 Fax: 301-480-3256 Email: stromberg@cber.fda.gov

MASAMI SUGANUMA
Group Leader Cancer Prevention Group Saitama Cancer Center 818 Komuro, Inamachi, Kitaadachi-gun Saitar, Japan 362-0806 Phone: 81-48-722-1111(4611) Fax: 81-48-722-1739 Email: masami@cancer-c.pref.saitama.jp

TAKASHI TAKAHASHl
Chief Aichi Cancer Center Research Institute Division of Molecular Oncology 1-1 Kanokoden, Chigusa Nagoya, Japan 464-8681 Phone: 81-52-762-6111 (7070) Fax: 81-52-764-2993 Email: tak@aichi-cc.jp

ANNE TATEM
National Cancer Institute 31 Center Drive Building 31, Room 11A03 MSC 2590 Bathesda, MD 20892 Phone: 301-496-5515 Fax: 301-496-3876 Email: tatema@mail.nih.gov

KATHRYN TAYLOR
Georgetown University 2233 Wisconsin Avenue, N.W. Suite 317 Washington, DC 20007 Phone: 202-687-0649 Fax: 202-687-8444 Email: taylork@georgetown.edu

KEIU YANAGAWA
General Affairs Division Japan Society for the Promotion of Science Japan Phone: 81-3-3263-1722 Fax: 81-3-3221-2470 Email: shomuka04@jsps,go.jp

ROSEMARY YANCIK
National Institute on Aging 7201 Wisconsin Avenue Gateway Building, Suite 3E327 Bethesda, MD 20892 Phone: 301-496-5278 Fax: 301-402-1784 Email: yancikR@nia.nih.gov

GEORGE YOO
National Institute on Dental and Craniofacial Research 30 Convent Drive Bethesda, MD 20892 Email: sg39V@nih,gov

KEITH ZACHMAN
National Institute of Child Health and Human Development 10 Center Drive Building 10, Room 9D42, MSC 1583 Bethesda, MD 20892 Phone: 301-496-6974 Fax: 301-402-0884 Email: zachmank@mail.nih.gov